Antheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy - Antheia
Summary
Antheia raised $56 million in Series C financing to expand commercialization of its first product, thebaine, and accelerate launches from its biosynthetic pharmaceutical ingredient pipeline. The company will use the capital to scale U.S. manufacturing, support domestic demand, and start strategic innovation programs in Singapore. It also plans to broaden its presence across Asia and deepen collaborations with investors, customers, and manufacturing partners. The announcement highlights Antheia’s role in addressing drug shortages and modernizing pharmaceutical supply chains with biosynthesis technology.
Funding
Amount
$56.0M
Total raised
Date
June 3, 2025
Announcement date
Investors
EDBI, Singapore Economic Development Board, Civilization Ventures, S-Cubed Capital, Sherpalo Ventures, Viking Global Investors
Lead investors
Company
http://www.antheia.bio/
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected